TS 1804
Alternative Names: TS-1804Latest Information Update: 28 Jan 2024
At a glance
- Originator Shandong Boan Biotechnology
- Developer Luye Pharma Group; Shandong Boan Biotechnology
- Class Antibodies; Antihaemorrhagics; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematoma; Solid tumours
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Haematoma in China (Parenteral)
- 28 Jan 2024 No recent reports of development identified for preclinical development in Solid-tumours in China (Parenteral)
- 01 Dec 2019 Luye Pharma acquires Shandong Boan Biotechnology